Rates of malignancies.
| Characteristics | cDMARD | TNFi | IFX | ETN | ADA | RTX |
|---|---|---|---|---|---|---|
| Patient-yrs | 3119 | 7162 | 1700 | 2842 | 2620 | 712 |
| No. malignancies | 39 | 47 | 10 | 21 | 16 | 6 |
| IR/1000 patient-yrs (95% CI) | 13 (8.9–17) | 6.6 (4.8–8.7) | 5.9 (2.8–11) | 7.4 (4.6–11) | 6.1 (3.5–9.9) | 8.4 (3.1–18) |
| IRR | Ref. | 0.52 (0.34–0.80) | 0.46 (0.23–0.93) | 0.59 (0.35–1.0) | 0.49 (0.27–0.88) | 0.68 (0.29–1.6) |
| aIRR* (95% CI) | Ref. | 0.98 (0.61–1.57) | 0.91 (0.44–1.9) | 1.1 (0.63–2.0) | 0.87 (0.47–1.6) | 1.0 (0.42–2.4) |
| aIRR** (95% CI) | Ref. | 1.2 (0.63–2.2) | 1.2 (0.44–3.1) | 1.3 (0.65–2.6) | 1.1 (0.51–2.2) | 1.2 (0.49–3.2) |
| IRR (95% CI) | — | Ref. | — | — | — | 1.3 (0.56–3.0) |
| aIRR* (95% CI) | — | Ref. | — | — | — | 1.0 (0.43–2.4) |
| aIRR*** (95% CI) | — | Ref. | — | — | — | 1.1 (0.42–2.7) |
↵* Age and sex.
↵** Full model.
↵*** Full model and prior biologic treatments. cDMARD: conventional disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitors; IFX: infliximab; ETN: etanercept; ADA: adalimumab; RTX: rituximab; IR: incidence rates; aIRR: adjusted incidence rate ratios; Ref.: reference group.